Pfizer Leads Jump in Pharmaceutical Lobbying

24-10-2013 Roll CallComments (0)


Large pharmaceutical companies may benefit from more customers under the Affordable Care Act, but they still lobby for fewer regulations in order to reduce the cost of bringing a new drug to market. New York-based Pfizer Inc., the largest research ...

Read more on Roll Call

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top